SUMMIT, N.J. - April 18, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Investorideas.com , a leader in sector stock research including defense and security stocks reports on recent DHS designations for Support Anti-terrorism by Fostering Effective Technologies Act of 2002, or "SAFETY Act", including private company, Wave Dispersion Technologies, and defense stocks Honeywell (NYSE: HON) and L-3 Communications (NYSE: LLL).
The SAFETY Act provides important legal liability protections for providers of Qualified Anti-Terrorism Technologies - whether they are products or services. The goal of the SAFETY Act is to encourage the development and deployment of new and innovative anti-terrorism products and services by providing liability protections. https://www.safetyact.gov/
The following technologies have been granted "Designation" pursuant to 6 U.S.C. § 441-444 (the Support Anti-terrorism by Fostering Effective Technologies Act of 2002, or "SAFETY Act") and 6 C.F.R. Part 25 (Regulations to Support Anti-terrorism by Fostering Effective Technologies):
Wave Dispersion Technologies, Inc. April 8, 2011 - Wave Dispersion Technologies, Inc., a New Jersey corporation provides WhisprWave® Small Craft Intrusion Barrier™ (the "Technology”), a modular, rapidly deployable floating security barrier system designed to enhance maritime security by deterring, delaying, or impeding small boats traveling at high speed from approaching protected targets. Anchoring of the Technology is customized for each installation and involves use of a commercially available marine-grade anchoring system, based on need. This Designation will expire on March 31, 2016.
Honeywell International Corporation March 16, 2011 - Honeywell International Corporation provides Enterprise Building Integrator. The Technology is a common software control architecture used to control a building or facility's security, life safety, and/or building maintenance (heating, cooling, ventilation, etc.) functions. The Technology also includes design, installation, integration, maintenance support, and customer training, and documentation services provided by Honeywell. The Designation for this Technology does not apply to or provide coverage for Acts of Terrorism that utilize chemical, biological, radiological, or nuclear (CBRN) agents or materials. This Designation will expire on March 31, 2016.
The Port Authority of New York and New Jersey February 28, 2011 - The Port Authority of New York and New Jersey provides the Protective Sleeve for Suspension Bridge Suspender Rope Damage Mitigation. The Technology is a sleeve made of steel and cementitious material. It is designed to increase resistance of bridge suspender ropes to various threats. This Designation will expire on March 31, 2016.
L-3 Communications Security and Detection Systems, Inc. and L-3 Communications Corporation February 23, 2011 - L-3 Communications Security and Detection Systems, Inc. and L-3 Communications Corporation provide the ProvisionTM SC-100 (also known as the Scout 100) and ProVisionTM 360 (also known as the SafeScoutTM 360). The Technology is a line of security portals that use millimeter-wave scanning technology to produce three-dimensional images of subjects to detect threat objects. The Technology also includes training, installation, maintenance services, manuals, and technical documents. This renewed Designation will expire on March 31, 2016.
Company Snapshot: Wave Dispersion Technologies, Inc
http://www.whisprwave.com
Wave Dispersion Technologies, Inc. reports the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT). Wave Dispersion Technologies, the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of Homeland Security (DHS) SAFETY Act Designation.
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation,” said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology,” said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Visit the showcase page on Investorideas.com:
http://www.investorideas.com/Companies/WDT/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Disclaimer/ disclosure our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: WDT has paid $500 for news release dissemination
www.InvestorIdeas.com/About/Disclaimer.asp
www.Investorideas.com
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
Monday, April 18, 2011
Biotech Stock Trading Alert; Aethlon Medical (OTCBB: AEMD) Trading up 12% in Morning Trading
Point Roberts
, WA - April 18, 2011 - www.Investorideas.com, a leader in sector stock research including biotech stocks, releases a biotech trading alert for Aethlon Medical (OTCBB:AEMD), a company with technology devices to address infectious disease and cancer. The stock is trading up at $ 0.14, up 0.02 (12.00%) up in early morning trading in volume of over 600,000 shares.
Company Snapshot
About Aethlon Medical (OTCBB: AEMD)
Visit the showcase profile at Investorideas.com
http://www.investorideas.com/CO/AEMD/
Recent News: Aethlon Medical (OTCBB: AEMD) Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV
http://www.investorideas.com/CO/AEMD/news/2011/04151.asp
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the UnitedStates and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All showcase company info is obtained from public filings, news, or directly from management. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com Source - Investorideas.com
Company SnapshotAbout Aethlon Medical (OTCBB: AEMD)
Visit the showcase profile at Investorideas.com
http://www.investorideas.com/CO/AEMD/
Recent News: Aethlon Medical (OTCBB: AEMD) Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV
http://www.investorideas.com/CO/AEMD/news/2011/04151.asp
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All showcase company info is obtained from public filings, news, or directly from management. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com Source - Investorideas.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV
SAN DIEGO - April 15, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that InvestorIdeas.com has released an interview with Aethlon CEO Jim Joyce regarding broad spectrum treatment strategies to address HIV, Hepatitis C and other infectious disease conditions. The interview can be accessed online at:
http://www.investorideas.com/CO/AEMD/news/2011/04141.asp
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
http://www.investorideas.com/CO/AEMD/news/2011/04141.asp
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
- Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
- Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
- Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
- Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Friday, April 15, 2011
WhisprWave Small Craft Intrusion Barrier and Vessel Exclusion Barrier Products designated as Qualified Anti-Terrorism Technologies
SUMMIT , N.J. - April 15, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Wave Dispersion Technologies, Inc. reports the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT). Wave Dispersion Technologies, the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of Homeland Security (DHS) SAFETY Act Designation.
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation," said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology," said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation," said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology," said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Thursday, April 14, 2011
Homeland Defense News; Wave Dispersion Technologies, Inc. Achieves U.S. Department of Homeland Security SAFETY Act Designation WhisprWave Floating Security Barriers Designated as a Qualified Anti-Terrorism Technology
SUMMIT, N.J. - April 14, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Wave Dispersion Technologies, Inc. (WDT) the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of Homeland Security (DHS) SAFETY Act Designation, and the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT).
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation,” said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology,” said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
>Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation,” said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology,” said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
>Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com
Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High Biodefense Stocks Sector Snapshot; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX ), (NasdaqGM: SIGA)
Point Roberts, WA - April 14, 2011 - Investorideas.com, a leader in sector stock research including biotech and biodefense stocks issues a trading alert on Emergent Biosolutions, Inc. (NYSE: EBS) as it hit a 52 week high in Wednesday’s trading. The Company reported its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress.
Biotech/ Biodefense Stocks Sector Snapshot ( as of close April 14 th)
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
ROCKVILLE, Md.--- Emergent BioSolutions Inc. (NYSE: EBS ) announced that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals and companies in the global vaccine industry.
"This award is a testament to the collective efforts of the Emergent BioSolutions team, who on a daily basis and all over the world, lives out the corporate mission – to protect life,” said Mr. El-Hibri. "Our team shares a passion and commitment to make vital contributions to address unmet and underserved medical needs. It is an honor to be recognized for the work that we do.”
In selecting the winner for this category, the distinguished panel of judges evaluated the finalists based on their commitment to disease prevention and treatment, leadership, contribution to company performance, communication, and vision, industry influence, and achievements in company positioning and status.
Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation
SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.
Full news: http://www.investorideas.com/CO/AEMD/news/2011/04121.asp
Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD),
Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Visit the Aethlon Medical (OTCBB: AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Emergent Biosolutions, Inc. (NYSE: EBS )
Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. www.emergentbiosolutions.com
About www.InvestorIdeas.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Research Biotech Stocks atInvestorideas.com
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Biotech/ Biodefense Stocks Sector Snapshot ( as of close April 14 th)
- Aethlon Medical (OTCBB: AEMD) closed at $0.1036 on over 242,000 shares, with its 52 week range of $0.096 - 0.35
- Dynasil Corporation (NASDAQ GM: DYSL) ended at $4.14, with a 52 week range of $ 2.35 - 7.48
- Emergent Biosolutions, Inc. (NYSE: EBS ) closed at $24,68 hitting its 52 week high; $14.11 - 25.24
- PharmAthene, Inc. (NYSE Amex: PIP) finished trading at $3.17, its 52 week range of $1.25 - 4.96
- Protalix BioTherapeutics, Inc. (AMEX: PLX ) closed at $7.24, up 0.15 (2.12%)
- Siga Technologies (NasdaqGM: SIGA ) ended trading at $13.4, up 0.48 (3.71%) on over 437,000 shares
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
ROCKVILLE, Md.--- Emergent BioSolutions Inc. (NYSE: EBS ) announced that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals and companies in the global vaccine industry.
"This award is a testament to the collective efforts of the Emergent BioSolutions team, who on a daily basis and all over the world, lives out the corporate mission – to protect life,” said Mr. El-Hibri. "Our team shares a passion and commitment to make vital contributions to address unmet and underserved medical needs. It is an honor to be recognized for the work that we do.”
In selecting the winner for this category, the distinguished panel of judges evaluated the finalists based on their commitment to disease prevention and treatment, leadership, contribution to company performance, communication, and vision, industry influence, and achievements in company positioning and status.
Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation
SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.
Full news: http://www.investorideas.com/CO/AEMD/news/2011/04121.asp
Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD),
Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Visit the Aethlon Medical (OTCBB: AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Emergent Biosolutions, Inc. (NYSE: EBS )
Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. www.emergentbiosolutions.com
About www.InvestorIdeas.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Research Biotech Stocks atInvestorideas.com
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
A Broad-Spectrum Treatment Strategy to Address HIV, Hepatitis-C (HCV) and other Infectious Disease Conditions; Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce
Point Roberts, WA. - April 14, 2011 � Investorideas.com, a leader in sector stock research presents a new interview in its series of biotech Q&A's, featuring Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD).
The Hemopurifier® from Aethlon Medical is a first-in-class medical device candidate to treat infectious disease. Human studies have documented that the Hemopurifier® can significantly reduce viral load in Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients in the absence of antiviral drugs. A study is currently underway to demonstrate the benefit of the Hemopurifier® as an adjunct to HCV drug therapy. Additional details can be accessed online at www.aethlonmedical.com
Q&A Interview
InvestorIdeas: How does your Hemopurifier® differ from drug therapies to treat infectious disease?
Mr. Joyce: Well, our approach is a complete departure from the consensus approach of introducing drug agents into the body to inhibit viral replication. As you are likely aware, these agents can have countering side effects or mechanisms of action that may not be fully understood. So, instead of adding agents into the body, our Hemopurifier® subtracts or removes viruses and other harmful particles from circulation without drug-related side effects. We think our therapeutic filtration approach could redefine the premise of how to treat infectious disease and we believe our strategy is far more innovative than another me-too drug inhibitor.
InvestorIdeas: Is a device that removes harmful particles from the body really considered to be innovative?
Mr. Joyce: The idea of a therapeutic filtration device that can remove harmful particles from circulation is not original. The basis of kidney dialysis, which keeps individuals with renal disease alive, is based on therapeutic filtration. However, like dialysis, previous therapeutic filtration strategies have sought to remove particles from circulation by molecule size, which is an indiscriminate approach that can also remove elements from circulation that are required for health. This factor has primarily limited the use of therapeutic filtration to niche markets. Our Hemopurifier® is truly innovative in the sense that we discriminate to selectively remove infectious viruses and other harmful particles from the entire circulatory system. It is this advancement that allows us to pursue opportunities in the much larger infectious disease and cancer markets.
InvestorIdeas: So it would seem your Hemopurifier® is positioned as a competitor to drug therapies.
Mr. Joyce: That is certainly not our intent. In fact, we expect to be an ally to the drug industry for several compelling reasons. First, if you really want to enhance or extend the benefit of drug therapies, you remove the strains of viruses that are causing drugs to fail and you do it without adding drug toxicity or interaction risks. But to fully unlock the capability of drug therapies you need to provide other complementary mechanisms that are beyond the reach of drugs. In that regard, we provide a strategy to address the toxins shed from viral surfaces to kill immune cells and particles known as exosomes that allow viruses to transport other disease-enhancing particles below the surveillance of the immune system. So our device in combination with drug therapy would seem to be a win-win scenario.
InvestorIdeas: What if a virus is not treatable with drug therapy?
Mr. Joyce: In reality, a vast majority of the viruses that are known to be infectious to man are not treatable with drugs. In scenarios that are life threatening, our Hemopurifer® is likely to be the sole strategy to address viral infections that are not treatable with drugs. For this reason, our Hemopurifier® is immensely valuable as new viruses like the coronavirus underlying the SARS outbreak of 2003 will emerge naturally in the future. We also face the looming threat of biological weapons purposely designed to defeat drug therapies. In either case, our Hemopurifier® provides a decision free first response that can augment the body's own immune response to such exposures, which is certainly more logical than an post-exposure strategy comprised of first identifying the virus that is killing people, and then establishing post-death research programs that may or may not yield a viable treatment candidate years after the fact.
InvestorIdeas: Thank you.
About Aethlon Medical ( OTCBB: AEMD )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011
800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
The Hemopurifier® from Aethlon Medical is a first-in-class medical device candidate to treat infectious disease. Human studies have documented that the Hemopurifier® can significantly reduce viral load in Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients in the absence of antiviral drugs. A study is currently underway to demonstrate the benefit of the Hemopurifier® as an adjunct to HCV drug therapy. Additional details can be accessed online at www.aethlonmedical.com
Q&A Interview
InvestorIdeas: How does your Hemopurifier® differ from drug therapies to treat infectious disease?
Mr. Joyce: Well, our approach is a complete departure from the consensus approach of introducing drug agents into the body to inhibit viral replication. As you are likely aware, these agents can have countering side effects or mechanisms of action that may not be fully understood. So, instead of adding agents into the body, our Hemopurifier® subtracts or removes viruses and other harmful particles from circulation without drug-related side effects. We think our therapeutic filtration approach could redefine the premise of how to treat infectious disease and we believe our strategy is far more innovative than another me-too drug inhibitor.
InvestorIdeas: Is a device that removes harmful particles from the body really considered to be innovative?
Mr. Joyce: The idea of a therapeutic filtration device that can remove harmful particles from circulation is not original. The basis of kidney dialysis, which keeps individuals with renal disease alive, is based on therapeutic filtration. However, like dialysis, previous therapeutic filtration strategies have sought to remove particles from circulation by molecule size, which is an indiscriminate approach that can also remove elements from circulation that are required for health. This factor has primarily limited the use of therapeutic filtration to niche markets. Our Hemopurifier® is truly innovative in the sense that we discriminate to selectively remove infectious viruses and other harmful particles from the entire circulatory system. It is this advancement that allows us to pursue opportunities in the much larger infectious disease and cancer markets.
InvestorIdeas: So it would seem your Hemopurifier® is positioned as a competitor to drug therapies.
Mr. Joyce: That is certainly not our intent. In fact, we expect to be an ally to the drug industry for several compelling reasons. First, if you really want to enhance or extend the benefit of drug therapies, you remove the strains of viruses that are causing drugs to fail and you do it without adding drug toxicity or interaction risks. But to fully unlock the capability of drug therapies you need to provide other complementary mechanisms that are beyond the reach of drugs. In that regard, we provide a strategy to address the toxins shed from viral surfaces to kill immune cells and particles known as exosomes that allow viruses to transport other disease-enhancing particles below the surveillance of the immune system. So our device in combination with drug therapy would seem to be a win-win scenario.
InvestorIdeas: What if a virus is not treatable with drug therapy?
Mr. Joyce: In reality, a vast majority of the viruses that are known to be infectious to man are not treatable with drugs. In scenarios that are life threatening, our Hemopurifer® is likely to be the sole strategy to address viral infections that are not treatable with drugs. For this reason, our Hemopurifier® is immensely valuable as new viruses like the coronavirus underlying the SARS outbreak of 2003 will emerge naturally in the future. We also face the looming threat of biological weapons purposely designed to defeat drug therapies. In either case, our Hemopurifier® provides a decision free first response that can augment the body's own immune response to such exposures, which is certainly more logical than an post-exposure strategy comprised of first identifying the virus that is killing people, and then establishing post-death research programs that may or may not yield a viable treatment candidate years after the fact.
InvestorIdeas: Thank you.
About Aethlon Medical ( OTCBB: AEMD )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011
800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Subscribe to:
Posts (Atom)